Revisiting substance P in migraine : a methodological approach inspired by anti-CGRP and anti-PACAP success
(2025) In Journal of Headache and Pain 26(1).- Abstract
Substance P, previously dismissed as a therapeutic target for migraine due to the failure of neurokinin-1 receptor antagonists, warrants renewed attention. Building on the success of therapies targeting the calcitonin gene-related peptide (CGRP) system and pituitary adenylate cyclase-activating peptide (PACAP) in migraine prevention, which highlight the importance of targeting peptides, this proposal reexamines substance P as a mediator in migraine pathophysiology. Using an established methodological framework, migraine-inducing properties of substance P can be evaluated through randomized, double-blind, placebo-controlled crossover studies involving healthy volunteers and individuals with a history of migraine. This approach aims to... (More)
Substance P, previously dismissed as a therapeutic target for migraine due to the failure of neurokinin-1 receptor antagonists, warrants renewed attention. Building on the success of therapies targeting the calcitonin gene-related peptide (CGRP) system and pituitary adenylate cyclase-activating peptide (PACAP) in migraine prevention, which highlight the importance of targeting peptides, this proposal reexamines substance P as a mediator in migraine pathophysiology. Using an established methodological framework, migraine-inducing properties of substance P can be evaluated through randomized, double-blind, placebo-controlled crossover studies involving healthy volunteers and individuals with a history of migraine. This approach aims to establish proof of concept for substance P’s role in migraine, laying the groundwork for investigations with animal and cell-based models and advancing the development of innovative treatments for patients refractory to current therapies.
(Less)
- author
- Pellesi, Lanfranco and Edvinsson, Lars LU
- organization
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- CGRP, Headache, Neurokinins, Pain, Substance P
- in
- Journal of Headache and Pain
- volume
- 26
- issue
- 1
- article number
- 22
- publisher
- Springer-Verlag Italia s.r.l.
- external identifiers
-
- pmid:39891050
- scopus:85217731609
- ISSN
- 1129-2369
- DOI
- 10.1186/s10194-025-01959-8
- language
- English
- LU publication?
- yes
- id
- 0f5f7dfe-0904-4d0a-aeaf-400a4e21b880
- date added to LUP
- 2025-06-09 11:45:15
- date last changed
- 2025-06-23 14:08:05
@article{0f5f7dfe-0904-4d0a-aeaf-400a4e21b880,
abstract = {{<p>Substance P, previously dismissed as a therapeutic target for migraine due to the failure of neurokinin-1 receptor antagonists, warrants renewed attention. Building on the success of therapies targeting the calcitonin gene-related peptide (CGRP) system and pituitary adenylate cyclase-activating peptide (PACAP) in migraine prevention, which highlight the importance of targeting peptides, this proposal reexamines substance P as a mediator in migraine pathophysiology. Using an established methodological framework, migraine-inducing properties of substance P can be evaluated through randomized, double-blind, placebo-controlled crossover studies involving healthy volunteers and individuals with a history of migraine. This approach aims to establish proof of concept for substance P’s role in migraine, laying the groundwork for investigations with animal and cell-based models and advancing the development of innovative treatments for patients refractory to current therapies.</p>}},
author = {{Pellesi, Lanfranco and Edvinsson, Lars}},
issn = {{1129-2369}},
keywords = {{CGRP; Headache; Neurokinins; Pain; Substance P}},
language = {{eng}},
number = {{1}},
publisher = {{Springer-Verlag Italia s.r.l.}},
series = {{Journal of Headache and Pain}},
title = {{Revisiting substance P in migraine : a methodological approach inspired by anti-CGRP and anti-PACAP success}},
url = {{http://dx.doi.org/10.1186/s10194-025-01959-8}},
doi = {{10.1186/s10194-025-01959-8}},
volume = {{26}},
year = {{2025}},
}